Rein Therapeutics, Inc. (RNTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on April 30, 2026, and the closing on May 4, 2026. Rein Therapeutics, Inc., a Delaware corporation, entered into a definitive underwriting agreement to raise capital through a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 50,000,000 shares of common stock sold at $1.00 per share.
- Net Proceeds: Approximately $46.1 million after underwriting discounts, commissions, and estimated expenses.
- Overallotment Option: Underwriter granted an option to purchase up to 7,500,000 additional shares within 45 days.
- Underwriter Warrants: Warrants issued to purchase 3% of shares sold (including overallotment) at an exercise price of $1.50 per share, exercisable for 5 years.
- Existing Financials: The filing does not provide current revenue, profit, cash flow, margin, or debt figures.
Material Changes and Agreements
The primary material change is the entry into an Underwriting Agreement with Konik Capital Partners, LLC. Additionally, the Company entered into a letter agreement with Bios Partners, L.P. regarding Series X Non-Voting Convertible Preferred Stock:
- Conversion Deferral: Bios entities agreed to defer the conversion of 12,232 Preferred Shares until the Company amends its charter to increase authorized common stock.
- Lock-up Agreement: Bios entities agreed not to sell or transfer Preferred Shares or underlying shares until April 30, 2029.
- Consideration: In exchange, the Company agreed to issue Bios entities warrants to purchase 3,000,000 shares of common stock at $1.00 per share.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the anticipated closing and net proceeds. Key risks include the Company's ability to satisfy closing conditions on a timely basis. The warrants issued to the underwriter are subject to a 180-day lock-up pursuant to FINRA rules. The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $46.1 million net proceeds.
- Confirm whether the underwriter exercises the 7,500,000 share overallotment option.
- Review the amended Restated Certificate of Incorporation to ensure authorized common stock is increased to accommodate the Bios Partners conversion.
- Monitor the 180-day lock-up expiration for underwriter warrants and the 2029 expiration for Bios Partners lock-up.
- Check subsequent filings for updated cash position and burn rate post-offering.